Curadel Pharma, based in Boston, Mass., is an audacious innovator aiming to prevent tumor resistance via disruptive zwitterionic radiopharma technology. Its novel, pan-tumor platform prevents tumor regrowth and resistance while eliminating collateral damage to healthy tissues. Curadel’s lead candidate, CPI-003, represents a potential best-in-class zwitterionic targeted alpha therapy (TAT) initially focused on the treatment of challenging rare cancers. The company is also developing image-guided surgical drugs. Its late-stage drug for ureter imaging is the subject of an exclusive distribution agreement with a Tier 1 medical device company and is currently under evaluation in a pivotal trial. For more information, visit www.curadelpharma.com or visit us on LinkedIn.
© 2025 Curadel Surgical Innovations, Inc. d/b/a Curadel Pharma